Given that IGFBP3 as the inhibitor of IGF1 bioavailability and activity has a vast array of biological functions and is involved in IR, obesity, inflammation, and oxidative stress, it seems reasonable to assume that its gene (IGFBP3) may contribute to the development and progression of NAFLD. The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatotic liver disease.